(NEW HAVEN, CT) Jun 27, 2019 — NGT BioPharma Consultants principal Sandy Farmer, Ph.D., has been tapped to contribute in the area of pharmaceutical R&D to a comprehensive report for Congress regarding the future of AI in healthcare. The National Academies of Sciences, Engineering, and Medicine identified Dr. Farmer as a key expert in the field who could assist the U.S. Government Accountability Office (GAO) in this project, which is in direct response to a request for information by the House Committee on Energy and Commerce and the Senate Committee on Health, Education, Labor, and Pensions.
Approximately 20 to 25 participants representing pharma, biotech, academia, and government will come together in July to help define the future of AI in pharmaceutical R&D towards advancing health care in the United States. The specific focus of this July meeting will be to elucidate the opportunities and challenges for AI in drug discovery and development, with a broad view to the scientific, economic, ethical, legal and social aspects thereof.
Dr. Farmer is a leading industry expert in making data actionable for pharmaceutical R&D organizations through the implementation of key data platforms, workflows, informatics tools, and user engagement. Additionally, his expertise includes combining AI capabilities with such actionable data to address current and future R&D objectives. Dr. Farmer is also a recognized expert in the field of structure-based drug discovery, which was one of the first scientific domains in pharmaceutical R&D to take advantage of AI.
Target delivery date to Congress is EOY 2020 for the full report.
